Pulse ·

Australia's updated asthma guidance: beyond the blue puffer

By Dr HB Lo, FACRRM 4 min read
Verdict Yes — worth knowing about

Australia's updated asthma guidance recommends anti-inflammatory reliever (AIR) therapy as the starting point for most adults and adolescents with asthma, replacing short-acting beta2 agonist (SABA) reliever therapy used alone. The change reflects evidence that SABA-only management treats the symptom while leaving the underlying airway inflammation unaddressed.

For anyone using a blue puffer more than twice weekly — or relying on it as their only asthma treatment — this is a prompt to raise the question with your GP. The conversation is straightforward and could meaningfully improve day-to-day asthma control.

What just happened

There is a quiet shift underway in how Australians are supposed to be managing asthma — and a significant proportion of people with the condition don’t know it has happened.

The Australian Asthma Handbook, which is the clinical standard for asthma management in this country, now recommends anti-inflammatory reliever (AIR) therapy as the starting treatment for most adults and adolescents. The short-acting beta2 agonist (SABA) reliever inhaler — the blue puffer, most commonly salbutamol — is no longer recommended as a standalone therapy for these populations. That is a meaningful shift from how most Australians with asthma were originally set up with their treatment.

Dr Brett Montgomery, chair of the National Asthma Council Australia’s guidelines committee, notes that approximately half of all Australians with asthma have poor control — and that a significant proportion of them are receiving either no inhaled corticosteroid therapy, or minimal corticosteroid therapy, leaving the inflammatory disease driving their symptoms unaddressed.

The both-and

Why the blue puffer has been the problem all along

The salbutamol reliever inhaler is, in pharmacological terms, extraordinarily persuasive. It works within minutes, relieves the sensation of chest tightness and wheeze, and is available over the counter. For a patient experiencing an asthma episode, it delivers what they need right now. The problem is that it does nothing about why the episode is happening.

Asthma is an inflammatory condition. The wheeze, the cough, the chest tightness — these are the downstream consequences of airway inflammation that has been building beneath the surface. A SABA inhaler dilates the airways temporarily; it does not reduce the inflammatory process that is narrowing them. Using it as the primary or sole treatment is the clinical equivalent of taking paracetamol every day for a headache driven by underlying tension — you’re treating the symptom, not the mechanism, and the mechanism keeps running.

The Australian Asthma Handbook now recommends:

  • AIR therapy — a combination inhaler with a bronchodilator and inhaled corticosteroid — as the starting treatment for most adults and adolescents
  • Maintenance-and-reliever therapy (MART) for patients needing regular treatment
  • SABA-only management is no longer recommended for adults and adolescents as a standalone approach

Using a SABA reliever more than twice a week is a flag that asthma is not adequately controlled. More strikingly, overuse — defined as twelve or more canisters per year — is associated with significantly elevated asthma-related mortality risk. The blue puffer can feel like the solution; in the context of ongoing inflammatory disease, heavy reliance on it is actually a marker of inadequate treatment.

The translation gap is the real clinical problem

The guidelines have shifted. The evidence has shifted. But Dr Montgomery’s observation is that translation from research evidence into clinical practice is consistently slow across medicine — and asthma is no exception. Many Australians who were prescribed a blue puffer years ago have never had their treatment reviewed in light of updated evidence.

A significant part of the challenge is patient expectation. Combination inhalers include an inhaled corticosteroid — a word that, for many patients, immediately triggers concern about “steroids.” Inhaled corticosteroids are not the same as systemic corticosteroids, which have a well-documented side-effect profile when taken orally or intravenously. Used correctly via an inhaler, they act locally on the airways at much lower doses. The lung is the target; systemic exposure is minimal.

But the salbutamol reliever is immediate and tangible. You take it and feel better within minutes. The anti-inflammatory component of a combination inhaler accumulates benefit over time — it doesn’t provide the same immediate feedback, and patients can conclude it “isn’t working” when it is actually building the therapeutic base that will reduce how often the reliever is needed. The message is slowly getting through, but it’s not there yet, as Dr Montgomery notes.

The over-the-counter access problem

One structural challenge the guidelines cannot fully fix: salbutamol is available over the counter in Australia without a prescription. People can, and do, simply buy more when they run out — without a GP visit, without a treatment review, and without any clinical prompt to ask whether their current approach is appropriate. The over-the-counter pathway makes SABA overuse easier to sustain and harder to detect in a clinical setting.

The National Asthma Council Australia has consumer-facing resources that can help people understand the difference between reliever and preventer therapies, and why the current guidelines recommend a different approach to the one many people have been using for years.

My two cents

If you have asthma and you’re using a blue reliever puffer more than twice a week — or if a blue puffer is the only asthma inhaler you have — that’s worth raising at your next GP visit. The treatment landscape has changed, and there is a real possibility that a combination inhaler would give you better day-to-day control.

Asthma that feels “managed” because the blue puffer works when you take it is not necessarily asthma that is under good inflammatory control. The distinction matters for long-term respiratory health, not just for how you feel on a given day.

If you were diagnosed with asthma more than a few years ago and haven’t had a treatment review since, ask your GP for one. The guidelines your current treatment is based on may have moved on.

Verdict: yes — a clinically important guideline shift; if you’re on SABA-only asthma treatment, the conversation with your GP is overdue.

Sources cited

  1. Asthma care goes beyond the blue puffer — Medical Republic, September 7, 2026. https://www.medicalrepublic.com.au/asthma-care-goes-beyond-the-blue-puffer/128824
  2. National Asthma Council Australia. https://www.nationalasthma.org.au
  3. Australian Asthma Handbook. https://www.asthmahandbook.org.au

Frequently asked questions

  • My GP gave me a blue reliever puffer and I use it most days. Is that a problem?

    Using a blue reliever (salbutamol) more than twice a week is a signal that asthma is not well controlled — it means underlying airway inflammation is active enough to cause regular symptoms. Australia's updated asthma guidance recommends discussing a combination anti-inflammatory inhaler with your GP if this applies to you. Don't adjust your inhaler treatment without speaking to your GP first.

  • What is anti-inflammatory reliever (AIR) therapy?

    AIR therapy uses a combination inhaler containing both a bronchodilator (for immediate symptom relief) and an inhaled corticosteroid (to address underlying airway inflammation). Every time the inhaler is used, it treats both the symptom and the inflammatory driver — rather than just providing short-term relief. Your GP can advise whether this type of inhaler is appropriate for your asthma.